Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies. A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology

Pierre L. Yong, John Boyle, Mark Ballow, Marcia Boyle, Melvin Berger, Jack Bleesing, Franciso A. Bonilla, Javier Chinen, Charlotte Cunninghamm-Rundles, Ramsay L Fuleihan, Lois Nelson, Richard L. Wasserman, Kathleen C. Williams, Jordan S. Orange*

*Corresponding author for this work

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

There are an expanding number of primary immunodeficiency diseases (PIDDs), each associated with unique diagnostic and therapeutic complexities. Limited data, however, exist supporting specific therapeutic interventions. Thus, a survey of PIDD management was administered to allergists/immunologists in the United States to identify current perspectives and practices. Among 405 respondents, the majority of key management practices identified were consistent with existing data and guidelines, including the provision of immunoglobulin therapy, immunoglobulin dosing and selective avoidance of live viral vaccines. Practices for which there are little specific data or evidence-based guidance were also examined, including evaluation of IgG trough levels for patients receiving immunoglobulin, use of prophylactic antibiotics and recommendations for complementary/alternative medicine. Here, variability applied to PIDD patients was identified. Differences between practitioners clinically focused upon PIDD and general allergists/immunologists were also identified. Thus, a need for expanded clinical research in PIDD to optimize management and potentially improve outcomes was defined.

Original languageEnglish (US)
Pages (from-to)255-263
Number of pages9
JournalClinical Immunology
Volume135
Issue number2
DOIs
StatePublished - May 1 2010

Fingerprint

Passive Immunization
Intravenous Immunoglobulins
Allergy and Immunology
Asthma
Complementary Therapies
Immunoglobulins
Viral Vaccines
Practice Management
Therapeutics
Disease Management
Immunoglobulin G
Guidelines
Anti-Bacterial Agents
Research
Surveys and Questionnaires
Allergists

Keywords

  • Antibiotic prophylaxis
  • Best practice
  • Complementary and alternative medicine
  • Intravenous immunoglobulin
  • Primary immunodeficiency
  • Subcutaneous immunoglobulin
  • hygiene

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Yong, Pierre L. ; Boyle, John ; Ballow, Mark ; Boyle, Marcia ; Berger, Melvin ; Bleesing, Jack ; Bonilla, Franciso A. ; Chinen, Javier ; Cunninghamm-Rundles, Charlotte ; Fuleihan, Ramsay L ; Nelson, Lois ; Wasserman, Richard L. ; Williams, Kathleen C. ; Orange, Jordan S. / Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies. A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. In: Clinical Immunology. 2010 ; Vol. 135, No. 2. pp. 255-263.
@article{e1070a1aa5804ae09be8ac8563c28500,
title = "Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies. A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology",
abstract = "There are an expanding number of primary immunodeficiency diseases (PIDDs), each associated with unique diagnostic and therapeutic complexities. Limited data, however, exist supporting specific therapeutic interventions. Thus, a survey of PIDD management was administered to allergists/immunologists in the United States to identify current perspectives and practices. Among 405 respondents, the majority of key management practices identified were consistent with existing data and guidelines, including the provision of immunoglobulin therapy, immunoglobulin dosing and selective avoidance of live viral vaccines. Practices for which there are little specific data or evidence-based guidance were also examined, including evaluation of IgG trough levels for patients receiving immunoglobulin, use of prophylactic antibiotics and recommendations for complementary/alternative medicine. Here, variability applied to PIDD patients was identified. Differences between practitioners clinically focused upon PIDD and general allergists/immunologists were also identified. Thus, a need for expanded clinical research in PIDD to optimize management and potentially improve outcomes was defined.",
keywords = "Antibiotic prophylaxis, Best practice, Complementary and alternative medicine, Intravenous immunoglobulin, Primary immunodeficiency, Subcutaneous immunoglobulin, hygiene",
author = "Yong, {Pierre L.} and John Boyle and Mark Ballow and Marcia Boyle and Melvin Berger and Jack Bleesing and Bonilla, {Franciso A.} and Javier Chinen and Charlotte Cunninghamm-Rundles and Fuleihan, {Ramsay L} and Lois Nelson and Wasserman, {Richard L.} and Williams, {Kathleen C.} and Orange, {Jordan S.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1016/j.clim.2009.10.003",
language = "English (US)",
volume = "135",
pages = "255--263",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies. A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. / Yong, Pierre L.; Boyle, John; Ballow, Mark; Boyle, Marcia; Berger, Melvin; Bleesing, Jack; Bonilla, Franciso A.; Chinen, Javier; Cunninghamm-Rundles, Charlotte; Fuleihan, Ramsay L; Nelson, Lois; Wasserman, Richard L.; Williams, Kathleen C.; Orange, Jordan S.

In: Clinical Immunology, Vol. 135, No. 2, 01.05.2010, p. 255-263.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies. A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology

AU - Yong, Pierre L.

AU - Boyle, John

AU - Ballow, Mark

AU - Boyle, Marcia

AU - Berger, Melvin

AU - Bleesing, Jack

AU - Bonilla, Franciso A.

AU - Chinen, Javier

AU - Cunninghamm-Rundles, Charlotte

AU - Fuleihan, Ramsay L

AU - Nelson, Lois

AU - Wasserman, Richard L.

AU - Williams, Kathleen C.

AU - Orange, Jordan S.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - There are an expanding number of primary immunodeficiency diseases (PIDDs), each associated with unique diagnostic and therapeutic complexities. Limited data, however, exist supporting specific therapeutic interventions. Thus, a survey of PIDD management was administered to allergists/immunologists in the United States to identify current perspectives and practices. Among 405 respondents, the majority of key management practices identified were consistent with existing data and guidelines, including the provision of immunoglobulin therapy, immunoglobulin dosing and selective avoidance of live viral vaccines. Practices for which there are little specific data or evidence-based guidance were also examined, including evaluation of IgG trough levels for patients receiving immunoglobulin, use of prophylactic antibiotics and recommendations for complementary/alternative medicine. Here, variability applied to PIDD patients was identified. Differences between practitioners clinically focused upon PIDD and general allergists/immunologists were also identified. Thus, a need for expanded clinical research in PIDD to optimize management and potentially improve outcomes was defined.

AB - There are an expanding number of primary immunodeficiency diseases (PIDDs), each associated with unique diagnostic and therapeutic complexities. Limited data, however, exist supporting specific therapeutic interventions. Thus, a survey of PIDD management was administered to allergists/immunologists in the United States to identify current perspectives and practices. Among 405 respondents, the majority of key management practices identified were consistent with existing data and guidelines, including the provision of immunoglobulin therapy, immunoglobulin dosing and selective avoidance of live viral vaccines. Practices for which there are little specific data or evidence-based guidance were also examined, including evaluation of IgG trough levels for patients receiving immunoglobulin, use of prophylactic antibiotics and recommendations for complementary/alternative medicine. Here, variability applied to PIDD patients was identified. Differences between practitioners clinically focused upon PIDD and general allergists/immunologists were also identified. Thus, a need for expanded clinical research in PIDD to optimize management and potentially improve outcomes was defined.

KW - Antibiotic prophylaxis

KW - Best practice

KW - Complementary and alternative medicine

KW - Intravenous immunoglobulin

KW - Primary immunodeficiency

KW - Subcutaneous immunoglobulin

KW - hygiene

UR - http://www.scopus.com/inward/record.url?scp=77950628870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950628870&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2009.10.003

DO - 10.1016/j.clim.2009.10.003

M3 - Article

C2 - 19914873

AN - SCOPUS:77950628870

VL - 135

SP - 255

EP - 263

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -